NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma

British Journal of Cancer

Volumn 101, Issue 8, 2009, Pages 1448-1455

  Flockhart, R J ^a   Armstrong, J L ^a   Reynolds, N J ^a   Lovat, P E ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

B RAF; COX 2; Melanoma; NFAT

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; B RAF KINASE; CYCLOOXYGENASE 2; CYCLOSPORIN A; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; SMALL INTERFERING RNA; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT 2; TRANSCRIPTION FACTOR NFAT 4; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; KNOCKOUT GENE; MELANOMA; MELANOMA CELL; METASTASIS; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; REPORTER GENE; SIGNAL TRANSDUCTION; WILD TYPE;

CALCINEURIN; CELL LINE, TUMOR; CYCLOOXYGENASE 2; HUMANS; MELANOMA; NFATC TRANSCRIPTION FACTORS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION;

EID: 70349962950     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605277     Document Type: Article

References (38)

1. Aspeslet L, Freitag D, Trepanier D, Abel M, Naicker S, Kneteman N, Foster R, Yatscoff R (2001) ISA(TX)247: a novel calcineurin inhibitor. Transplant Proc 33(1-2): 1048-1051
2. Botti C, Seregni E, Ferrari L, Martinetti A, Bombardieri E (1998) Immunosuppressive factors: role in cancer development and progression. Int J Biol Markers 13(2): 51-69
3. Buchholz M, Ellenrieder V (2007) An emerging role for Ca2+/calcineurin/ NFAT signaling in cancerogenesis. Cell Cycle 6(1): 16-19
4. Chwirot BW, Kuzbicki L (2007) Cyclooxygenase-2 (COX-2): first immuno-histochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours. Melanoma Res 17(3): 139-145
5. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky Jr WE, You MJ, DePinho RA, McMahon M, Bosenberg M (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41(5): 544-552
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892): 949-954
7. Dhomen N, Marais R (2007) New insight into BRAF mutations in cancer. Curr Opin Genet Dev 17(1): 31-39
8. Dumont FJ (2000) FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem 7(7): 731-748
9. Flockhart RJ, Diffey BL, Farr PM, Lloyd J, Reynolds NJ (2008) NFAT regulates induction of COX-2 and apoptosis of keratinocytes in response to ultraviolet radiation exposure. FASEB J 22(12): 4218-4227
10. Gogas H, Polyzos A, Stavrinidis I, Frangia K, Tsoutsos D, Panagiotou P, Markopoulos C, Papadopoulos O, Pectasides D, Mantzourani M, Middleton M, Vaiopoulos G, Fountzilas G (2006) Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 17(12): 1835-1841
11. Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS (2008) The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 14(1): 230-239
12. Halilovic E, Solit DB (2008) Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr Opin Pharmacol 8(4): 419-426
13. Hogan PG, Chen L, Nardone J, Rao A (2003) Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17(18): 2205-2232
14. Ichida M, Finkel T (2001) Ras regulates NFAT3 activity in cardiac myocytes. J Biol Chem 276(5): 3524-3530
15. Iniguez MA, Martinez-Martinez S, Punzón C, Redondo JM, Fresno M (2000) An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem 275(31): 23627-23635
16. Jauliac S, Lopez-Rodriguez C, Shaw LM, Brown LF, Rao A, Toker A (2002) The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol 4(7): 540-544
17. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23(37): 6292-6298
18. Kuzbicki L, Sarnecka A, Chwirot BW (2006) Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Res 16(1): 29-36
19. Lovat PE, Corazzari M, Armstrong JL, Martin S, Pagliarini V, Hill D, Brown AM, Piacentini M, Birch-Machin MA, Redfern CP (2008) Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress. Cancer Res 68(13): 5363-5369
20. Macian F, Garcia-Rodriguez C, Rao A (2000) Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun. EMBO J 19(17): 4783-4795
21. Macian F, Lopez-Rodriguez C, Rao A (2001) Partners in transcription: NFAT and AP-1. Oncogene 20(19): 2476-2489
22. Medyouf H, Ghysdael J (2008) The calcineurin/NFAT signaling pathway: a novel therapeutic target in leukemia and solid tumors. Cell Cycle 7(3): 297-303
23. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436(7051): 720-724
24. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J (2008) Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68(12): 4853-4861
25. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS (2009) CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58(1): 90-96
26. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS (2003) High frequency of BRAF mutations in nevi. Nat Genet 33(1): 19-20
27. Sanna B, Bueno OF, Dai YS, Wilkins BJ, Molkentin JD (2005) Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth. Mol Cell Biol 25(3): 865-878
28. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7(4): 295-308
29. Sharma A, Tran MA, Liang S, Sharma AK, Amin S, Smith CD, Dong C, Robertson GP (2006) Targeting mitogen-activated protein kinase/ extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res 66(16): 8200-8209
30. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP (2005) Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65(6): 2412-2421
31. Sheil AG (1998) Cancer in immune-suppressed organ transplant recipients: aetiology and evolution. Transplant Proc 30(5): 2055-2057
32. Stalder M, Birsan T, Hubble RW, Paniagua RT, Morris RE (2003) In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. J Heart Lung Transplant 22(12): 1343-1352
33. Tsukamoto H, Irie A, Nishimura Y (2004) B-Raf contributes to sustained extracellular signal-regulated kinase activation associated with inter-leukin-2 production stimulated through the T cell receptor. J Biol Chem 279(46): 48457-48465
34. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6): 855-867
35. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD (2004) Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94(1): 110-118
36. Wojciechowska K, Lewinski A (2006) BRAF mutations in papillary thyroid carcinoma. Endocr Regul 40(4): 129-138
37. Yu H, van Berkel TJ, Biessen EA (2007) Therapeutic potential of VIVIT, a selective peptide inhibitor of nuclear factor of activated T cells, in cardiovascular disorders. Cardiovasc Drug Rev 25(2): 175-187
38. Zaichuk TA, Shroff EH, Emmanuel R, Filleur S, Nelius T, Volpert OV (2004) Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J Exp Med 199(11): 1513-1522